In Re: National Prescription Opiate Litigation

Track this case

Case overview

Case Number:

1:17-md-02804

See also:

Court:

Ohio Northern

Nature of Suit:

P.I.: Other

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

Dan Aaron Polster (MDL 28

Firms

Companies

Government Agencies

Sectors & Industries:

  1. July 13, 2022

    Walgreens Says SF Opioid Case Has 'Fatal Flaw' As Trial Ends

    Left as the lone defendant in a bellwether bench trial brought by San Francisco over the city's opioid crisis, Walgreens argued during its closing arguments Wednesday that the city didn't show any evidence its pharmacists dispensed medically inappropriate drugs — a "fatal flaw" in the case against it.

  2. July 12, 2022

    $58M Opioid Deal Cuts Allergan, Teva From SF Bellwether Trial

    San Francisco struck settlements worth almost $58 million with Allergan and Teva Pharmaceuticals on Tuesday in the sole ongoing trial over the pharmaceutical industry's role in a nationwide crisis of opioid abuse, leaving Walgreens as the last company in the closely watched showdown.

  3. July 08, 2022

    W.Va. Opioid Verdict Widens Judge-Jury Split On Vital Theory

    A resounding victory by drug distributors in a bench trial over West Virginia's catastrophic opioid crisis underscores a growing gulf between judges and juries in broader opioid litigation, with judges increasingly rejecting a crucial legal theory while juries embrace it.

  4. June 30, 2022

    SF Says Pharmaceutical Cos. Created City's Opioid Crisis

    A lawyer for San Francisco has told a California federal judge overseeing a bellwether bench trial in multidistrict opioid litigation that Anda, Allergan, Teva and Walgreens promoted and distributed the powerful painkillers in ways that created a public nuisance that endangered the health and safety of the city's residents.

  5. June 27, 2022

    As Opioid Trial Ends, Judge Jokes Of 'Generous' Time Limits

    A San Francisco federal judge who put strict time limits on a bellwether bench trial in multidistrict opioid litigation noted Monday that both sides wrapped up their cases within their allotted 45 hours, prompting him to wonder to courtroom chuckles if he "was just too generous."

  6. June 16, 2022

    Yale Law Prof Defends Allergan In SF Opioid Trial

    A Yale University law professor — the final live defense witness in a bellwether opioid bench trial in San Francisco — testified Thursday that Allergan entities were not responsible for the conduct of Alpharma, a company that had owned a branded opioid called Kadian that Allergan later acquired.

  7. June 15, 2022

    SF Opioid Crisis Not From Allergan's Market Share, Judge Told

    An economics expert for Allergan testified Wednesday in a bellwether opioid bench trial that the "extremely small" market share and promotion done for the company's two branded opioids could not have substantially contributed to San Francisco's opioid crisis.

  8. June 14, 2022

    Remand Denial Raises Question In W.Va. Opiate Litigation

    The West Virginia attorney general on Tuesday asked the Ohio federal judge overseeing the multidistrict litigation over the opioid crisis to clarify under what conditions the state's medical professional liability law applies in suits brought by municipalities against health care providers.

  9. June 13, 2022

    Judge Breyer Pitches Law Chat As SF Opioid Trial Nears End

    With a high-stakes bench trial winding down over San Francisco's claims that Teva, Allergan, Anda and Walgreens illegally fueled the city's opioid epidemic, U.S. District Judge Charles Breyer judge indicated Monday he'd like to schedule a discussion exploring the law governing the case separate from the facts presented at trial.

  10. June 13, 2022

    Ohio Counties Open To Lowering Opioid Damages Request

    Two Ohio counties told a federal judge Monday they still want billions to address the fallout from the opioid epidemic from three large pharmacy chains that a jury found contributed to the crisis, although the counties also said that questions about the size of the impacted population could warrant a smaller payout.